About Us
We are developing Protein-Based Regenerative Medicine for major human disease therapies. Our goal is to develop innovative protein drugs including transcription factor (TF) protein drugs that can treat major human diseases, with the ultimate aim of improving human health and enhancing human longevity.
About Us
OUR COMPANY
Founded in 2012 and headquartered in Michigan, USA, Qurgen is a clinical-stage biotechnology company focusing on regenerative medicine and innovative drug research and development.
With a global layout, Qurgen runs its headquarters and R&D center in the United States, and has subsidiaries in Shanghai and Suzhou of China, where the industrial production base is located. It also builds a joint laboratory with the Institutes of Biomedical Sciences, Fudan University, to accelerate clinical transformation of scientific achievements and drive the development of global regenerative medicine and innovative pharmaceutical industry.
With a global layout, Qurgen runs its headquarters and R&D center in the United States, and has subsidiaries in Shanghai and Suzhou of China, where the industrial production base is located. It also builds a joint laboratory with the Institutes of Biomedical Sciences, Fudan University, to accelerate clinical transformation of scientific achievements and drive the development of global regenerative medicine and innovative pharmaceutical industry.
MSSION & VISION
Break the boundaries of life with protein technology and benefit critically ill patients with original innovative drugs.
Become a global leader in protein regenerative medicine and tumor reversal therapy, and build a China-originated, world-class innovative biopharmaceutical brand.
Become a global leader in protein regenerative medicine and tumor reversal therapy, and build a China-originated, world-class innovative biopharmaceutical brand.
OUR HISTORY
January 13, 2026
Dr. Chai Yan joined as Senior Vice President, Corporate Secretary, and CEO of Suzhou Fuent, responsible for business development and public listing.
December 2025
Completed an 8-year long-term safety study in non-human primates; no teratomas or tumors were observed following high-dose administration.
June–July 2025
Qurgen successfully produced two additional GMP-scale batches of SON-DP anti-tumor transcription factor protein drug for use in Phase I clinical trials in the U.S. and China.
June–July 2024
Qurgen successfully produced two GMP-scale batches of the anti-tumor transcription factor protein drug SON-DP. These batches met FDA protein drug quality standards and were supplied to Phase I clinical trials in the U.S. and China.
February 2024
Qurgen’s 30,000 sq. ft. GMP protein drug manufacturing facility was completed and commissioned.
December 2023
Suzhou Fuent completed a follow-on financing round of RMB 50 million, with a post-money valuation of RMB 625 million.
September 2012
Qurgen Inc. was founded in Michigan, USA, holding core technologies in protein delivery and in situ cell reprogramming.
November 28, 2014
Fuent Biotechnology (Shanghai) Co., Ltd. was established, marking the launch of the China R&D and Operations Center in Zhangjiang Pharma Valley.
December 2015
Signed an intellectual property licensing agreement with Wayne State University.
March 2016
Established a joint laboratory with the Institutes of Biomedical Sciences (IBS), Fudan University.
July 25, 2016
Wuxi Fuent Biotechnology Co., Ltd. was established (manufacturing center).
August 2016
Completed Pre-Series A financing.
October 18, 2016
Shanghai Zhongliu Pharmaceutical Technology Co., Ltd. was established.
2018
Completed Series A financing.
2019
GLP pharmacokinetic (PK) and toxicology studies were completed at Charles River Laboratories, confirming the favorable safety profile of QQ-SON.
March 30, 2021
Suzhou Fuent Pharmaceutical Co., Ltd. was established (China headquarters), launching the company’s industrialization strategy.
July 2021
Wuxi Fuent was fully relocated to Suzhou Life & Health Town; a new laboratory was constructed and commissioned in September 2021.
December 2022
Suzhou Fuent completed its first round of financing of RMB 125 million, with a post-money valuation of RMB 575 million.
December 7, 2022
Qurgen received FDA IND approval (IND #152226) for the Phase I clinical trial of SON-DP.
December 2023
Suzhou Fuent completed a follow-on financing round of RMB 50 million, with a post-money valuation of RMB 625 million.
February 2024
Qurgen’s 30,000 sq. ft. GMP protein drug manufacturing facility was completed and commissioned.
June–July 2024
Qurgen successfully produced two GMP-scale batches of the anti-tumor transcription factor protein drug SON-DP. These batches met FDA protein drug quality standards and were supplied to Phase I clinical trials in the U.S. and China.
June–July 2025
Qurgen successfully produced two additional GMP-scale batches of SON-DP anti-tumor transcription factor protein drug for use in Phase I clinical trials in the U.S. and China.
December 2025
Completed an 8-year long-term safety study in non-human primates; no teratomas or tumors were observed following high-dose administration.
January 13, 2026
Dr. Chai Yan joined as Senior Vice President, Corporate Secretary, and CEO of Suzhou Fuent, responsible for business development and public listing.